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Affymetrixin SNP 5.0 mikrosirua. Tavoitteena oli toteuttaa koko genomin 
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The aim of the study was to carry out the genotyping of the human genome by using 
Affymetrix Genome-Wide Human Array SNP 5.0 as the array platform. The aim was 
further to carry out the whole genome association study to a large Finnish population 
cohort by using DIPP project material which had been collected over a period of 15 
years from diabetes patient samples. With the help of the array it will be possible to 
find statistically significant SNP that can help us for gain deeper understanding of 
type 1 diabetes genes. 
 
The whole genome was determined from a total of 245 patient samples, of which 153 
were diabetes positive samples and the remaining 92 samples were controls. The 
genotyping calls were determined from the gathered array picture data by using 
Affymetrix Genotyping Console (GTC) software. From the results of the genotyping 
calls, single point association tests were performed by using Bioconductor. With the 
help of the software it was possible to determine statistically the most significant 
SNPs of all 500,568.  
 
The goal of this study was achieved and as a result, dozens of statistically significant 
SNPs were found. With the help of these results we can determine the genes where 
these SNPs are located and explore the role of these genes in type 1 diabetes. 
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1 AIM OF THE STUDY 
The disease association studies that have been done during the last 20 years were done 
using only few SNPs because genotyping has been too expensive and slow. This has 
been a major limitation in understanding disease coding genes. Now that the 
technology of microarrays has been developed rapidly producing fast and cheap 
platforms, genotyping of hundreds of thousands of SNPs is feasible. This study aimed 
to carry out the first whole genome scan in the large population cohort -the DIPP 
cohort- to help further understanding of type 1 diabetes genes. Such a study has never 
been condacted before. 
 
2 INTRODUCTION 
The Diabetes Prediction and Prevention Project (DIPP) is a study where general 
population newborns are screened of increased risk for type 1 diabetes in the 
University Hospitals of Turku, Tampere and Oulu. DIPP was launched in Finland in 
1994 and since then over 100 000 newborns have been screened. Infants with risk 
HLA-DQB1 genotypes (DR3-DQ2/DR4-DQ8, DR4-DQ8/X, DR3-DQ2/Y, where 
X≠DR3-DQ2, DQB1*0301, DQB1*0602 and Y≠DR7-DQ2, DQB1*0301, *0302, 
*0602 or *0603), are followed and sampled at intervals of 3–12 months. Islet cell 
antibodies (ICA) are analyzed from all serum samples and if they are found positive, 
IAA, GADA and IA-2A are tested in all samples available from that ICA-positive 
subject (Hermann 2006a). To date over 8 500 children carrying increased genetic risk 
of type 1 diabetes have participated in the study and over 110 of them have progressed 
to clinical diabetes (http://research.utu.fi/dipp).  
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3 THEORETICAL BACKROUND 
3.1 Diabetes 
Diabetes is a chronic metabolic disorder characterized by elevated levels of blood 
glucose, or sugar. It occurs when the body produces little or no insulin or when cells 
not respond appropriately to the insulin that is produced. Hyperglycaemia, or raised 
blood sugar, is a common phenomenon in uncontrolled diabetes and over time it leads 
to serious damage to many of the body's systems, especially the nerves and blood 
vessels (World Health Organization 2008). 
According to the International Diabetes Institute there are three main diabetes types: 
type 1, also known as juvenile onset diabetes (T1D), type 2 also known as adult-onset 
diabetes and gestational diabetes which is first diagnosed during pregnancy. Type 1 
diabetes is characterized by lack of insulin production. Without daily administration of 
insulin, Type 1 diabetes is rapidly fatal. Type 2 diabetes results from the body’s 
ineffective use of insulin. Type 2 diabetes comprises 90% of people with diabetes 
around the world, and is largely the result of excess body weight and physical 
inactivity. The symptoms may be similar to those of Type 1 diabetes, but are often 
less marked. As a result, the disease may be diagnosed several years after onset, once 
complications have already arisen. Until recently, type 2 diabetes was seen only in 
adults but it is now also occurring in obese children (World Health Organization 
2009). 
The World Health Organization (WHO) estimates that more than 180 million people 
worldwide have diabetes. This number is likely to more than double by the year 2030.  
3.1.1 Type 1 diabetes 
Type 1 diabetes occurs in about 10-15% of all cases of diabetes. It usually occurs in 
people under the age of 30, but can breakout at any age. 
Type 1 diabetes occurs when the body’s immune system destroys the cells of the 
pancreas that produce insulin (autoimmune response). Specific antibodies may be 
present in the blood during this time. This process may take several years. It is thought 
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that a virus or chemical may trigger this reaction in people who have a genetic 
predisposition.  Only a small number of people have this genetic risk. 
In the disease the pancreas no longer produces insulin and so the glucose cannot enter 
the muscle and other body cells, resulting in a rapid buildup of glucose and ketones in 
the blood stream.  The kidneys attempt to wash this excess glucose out of the body so 
there is an increase in the amount of urine produced, and the person becomes very 
thirsty. If glucose cannot be used by the cells, the body breaks down fat as an 
alternative energy source.  The by-products of fat breakdown are ketones.  If too many 
ketones accumulate in the bloodstream they may cause serious illness, and result in a 
medical emergency. The onset of type 1 diabetes may be quite sudden and often the 
person shows rapid and unplanned weight loss over several weeks. In adults it may 
appear more slowly (Internation Diabetes Institute 2009). 
3.1.2 The genetics of type 1 diabetes 
In general T1D is considered as a complex genetic trait, i.e., not only do multiple 
genetic loci contribute to susceptibility, but environmental factors also play a major 
role in determining risk. A large body of evidence indicates that inherited genetic 
factors influence both susceptibility and resistance to the disease. Genetic 
susceptibility in family members is clearly dependent on the degree of genetic identity 
with the proband (the first affected family member), and in fact the risk of T1D in 
families has a non-linear correlation with the number of alleles shared with the 
proband; the highest risk is observed in monozygotic twins (100% sharing), followed 
by first and second degree relatives (50% and 25% sharing respectively).  
In studies evaluating genes for association with disease status in either case-control or 
family-based studies two chromosomal regions have emerged with consistent and 
significant evidence of association with T1D across multiple studies. These are the 
human leukocyte antigen (HLA) region at chromosome 6p21.3 and the insulin gene 
region at chromosome 11p15 (Table 3.).  
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Tabel 1. The HLA Classes (Al-Mutairi H. & Mohnsen A. 2007) 
Class I genes: HLA-A, HLA-B, HLA-C encode class I HLA 
antigens, located on the 
surface of all nucleated 
cells 
Class II genes: HLA-DR, HLA-DQ, 
HLA-DP 
produce class II HLA 
antigens that are found 
exclusively on B-
lymphocytes, 
macrophages, epithelial 
cells of Langerhans, and  
activated T-lymphocytes 
Class III genes: C2, properdin factor B, 
C4D and C4B 
code for complement 
components, 21-
hydroxylase and products 
involved in T-cell-
mediated inflammation, 
such as TNF-A and TNF-
B, and acute phase protein 
 
In a recently conducted genome-wide linkage analysis, which included five complete 
genome scans (Davies et al. 1994, Hashimoto et al. 1994, Concannon et al. 1998, 
Mein et al. 1998, Nerup 2001 and Pociot 2002) and a combined analysis of the UK 
and US genome scan data (Cox et al. 2001), identification of the genetic determinants 
for T1D was attempted. These studies suggest that close to 20 loci, with variable 
degrees of linkage evidence, might be influencing T1D risk. The largest contribution 
from a single locus (IDDM1) comes from several genes located in the MHC (major 
histocompatibility complex) complex on chromosome 6p21.3 accounting for at least 
40% of familial aggregation of this disease. The genes of the MHC region are 
classified into four families, classes I, II, III and IV. The strongest genetic 
susceptibility to T1D is conferred by HLA class II gene alleles (Table 1). HLA class II 
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molecules, particularly DR and DQ, account for approximately 40% out of the genetic 
risk for T1D development (Al-Mutairi H. & Mohnsen A. 2007). 
 
Tabel 2. HLA haplotypes and type 1 diabetes (Al-Mutairi H. & Mohnsen A. 2007) 
DR 3 DQA1*0501 DQB1*0201 DRB1*0301 
DR 4 DQA1*0301 DQB1*0302 DRB1*0401 
DR 4 DQA1*0301 DQB1*0302 DRB1*0405 
Predisposing haplotypes 
DR 2 DQA1*0102 DQB1*0502 DRB1*1601 
DR 4 DQA1*0301 DQB1*0302 DRB1*0402 
DR 4 DQA1*0301 DQB1*0302 DRB1*0404 
Protective haplotypes 
DR 2 DQA1* 0102 DQB1*0602 DRB1*1501 
DR 6 DQA1*0101 DQB1*0503 DRB1*1401 
DR 7 DQA1*0201 DQB1*0303 DRB1*0701 
 
Approximately 30% of T1D patients are heterozygous for HLA-DQA1*0501-
DQB1*0201/DQA1*0301-DQB1*0302 alleles which have formerly been referred to 
as HLA-DR3/4 and are for simplification usually shortened to HLA-DQ2/DQ8 (Table 
2). A particular HLA-DQ6 molecule (HLA-DQA1*0102-DQB1*0602) is associated 
with dominant protection from the disease (Pociot et al. 2002).  
In the recent study (Hermann et al. 2006b) evidence was found for the assumption that 
the PTPN22 C1858T variant regulates type 1 diabetes-specific autoimmunity and 
strongly affects the progression from preclinical to clinical diabetes in ICA+ 
individuals. It was shown that PTPN22, INS and HLA-DRB1 had an additive effect 
on the emergence of IAA. The strong effect of PTPN22 on disease susceptibility (p = 
2.1 x 10(-8)) was more pronounced in males (p = 0.021) and in subjects with non-
DR4-DQ8/low-risk HLA genotypes (p = 0.0004). 
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Tabel 3. Susceptibility loci of type 1 diabetes (Al-Mutairi H. & Mohnsen A. 2007) 
Loci Chromosome Candidate Genes 
IDDM1 6p21.3 HLADR/DQ 
IDDM2 11p15.5 INSULIN (INS) VNTR 
PTPN22 1p13 PTPN22 (LYP) 
SUMO4 6q25 (IDDM5) SUM04 
IDDM3 15q26 - 
IDDM4 11q13 LRP5, FADD 
IDDM5 6q25 MnSOD, SUMO4 
IDDM6 18q12-q21 JK(Kidd), ZNF236, BLC2 
IDDM7 2q31-33 NEUROD 
IDDM8 6q25-27 - 
IDDM9 3q21-25 - 
IDDM10 10p11-q11 GAD2 
IDDM11 14q24-q31 ENSA, SEL-1L 
IDDM12 2q33 CTLA-4, CD28 
IDDM13 2q34  
IDDM15 6q21  
IDDM16 14q32  
IDDM17 10q25  
IDDM18 5q31.1-33.1 ILI2B 
 
3.2 Single Nucleotide Polymorphisms 
The variations in our DNA sequence that cause or contribute to disease are called 
either mutations or polymorphisms, based on their frequency in the population. DNA 
sequence variants that occur in > 1% of the population are called polymorphisms, and 
those that occur in less than one percent of individuals are called mutations. Mutations 
are responsible for the relatively rare single-gene Mendelian disorders, while 
polymorphisms are associated with the more common complex genetic disorders 
(Tebbutt S. 2007). Single nucleotide polymorphisms, SNPs, are common, small 
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variations that occur in human DNA throughout the genome. These polymorphic 
markers can be used to map and identify important genes associated with diseases. 
There are around 10 million common SNPs that constitute 90% of the variation in the 
current human population (The International HapMap Consortium, 2003). There are 
SNPs approximately every 200 or 300 base-pairs in the human genome. It has been 
estimated that the human genome contains more than 5 million common SNPs with 
minor allele frequencies (MAF) ≥ 10% [1–3], and 7.5 million common SNPs with 
MAF ≥ 5% (Hao K. et al 2008). Recently high-density SNP arrays have allowed 
researchers to conduct whole-genome association studies (WGAS). Using these arrays 
we measure the probability of association between a linked causative SNP marker and 
a trait. 
3.3 DNA Microarray 
DNA microarrays can be classified according to the type of probes on the array 
(cDNA, oligonucleotides, and genomic fragments), their generation and 
immobilization. In many cases presynthesized molecules, such as PCR products, 
oligonucleotides or isolated DNA are deposited on the array either by contact printing 
(using metal pins that carry small volumes of probe solution due to capillary action) or 
by non-contact printing, when probe solution is dispensed by ink-jet printing. Several 
companies generate high-density microarrays by synthesizing oligonucleotides in situ. 
The synthesis is either based on specific base deprotection by light which is 
coordinated by photomasks or digital micromirror devices, or on chemical 
deprotection and the use of ink-jet technology. SNP genotyping microarrays can be 
manufactured in different ways, including in situ synthesis or immobilization of the 
locus-/allele-specific oligonucleotides on the array and by using tag arrays, which act 
as hybridization partners for the allele-/locus-specific oligonucleotides, tailed with 
sequence complementary to the tag (DNA Microarrays, Nuber 2005). 
Affymetrix chips use short oligonucleotide probe quarters to interrogate each 
dimorphic site and include up to 500 000 SNPs. Each quarter consist of a perfect 
match (PM) and a mismatch (MM) 25-mer, corresponding to both alleles (arbitrarily 
named allele A and allele B) of a known SNP, yielding four different probes – PMA, 
PMB, MMA and MMB. This forms the basic unit of quantifying allele-specific 
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hybridization. Each SNP has multiple quartets querying different strands and shifts 
surrounding the polymorphic site (Xiao Y. et al. 2007).  
3.3.1 High-density SNP genotyping array 
High-density single nucleotide polymorphism (SNP) genotyping
 
arrays have been 
used for copy number variation (CNV)
 
detection and analysis, because the arrays can 
serve a dual
 
role for SNP- and CNV-based association studies. They also can
 
provide 
considerably higher precision and resolution than traditional
 
techniques. CNV refers to 
genomic segments of at least one kb in size, for
 
which copy number differences have 
been observed in comparison
 
to reference genome assemblies. Multiple large-scale 
studies have reported prevalent CNVs in
 
humans, suggesting that they may account 
for a significant portion
 
of phenotypic variation. The precise and comprehensive 
identification
 
of CNVs would greatly benefit the functional analysis of human
 
genome 
variation, and complement current genome-wide association
 
studies that use SNPs. 
(Wang K. 2008) 
3.3.2 Selection of the array type 
After making decision of starting to use the DNA microarray technology, one of the 
first considerations to make is to select an appropriate array type. The next step is to 
consider where the array will be acquired from. The most usual choice is to buy a 
ready-made array from some commercial chip producer. The most known commercial 
ready-made array producers are Affymetrix, Illumina, Agilent Technologies, Applied 
Biosystems and Roche (Chu W. 2005). It is also possible to buy a custom-made array 
where the buyer can decide the genes that will be spotted on to chip. (Kulta A. 2002). 
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Figure 1 Affymetrix Genome-Wide Human SNP Array 5.0 (Nature Methods, June 
2008) 
The selected Affymetrix Genome-Wide Human SNP Array 5.0 (Figure 1) is a high 
density array that evenly covers coding and non coding regions. This way array 
provides high information content in most of the genome. The SNPs were selected 
using known linkage disequilibrium patterns. The pattern of linkage disequilibrium 
(LD) is critical for association studies, in which disease-causing variants are identified 
by allelic association with adjacent markers (Mueller JC. 2005). In the present study 
this array type was selected, since it has the required SNP density to capture most of 
the genetic variation across genome.  
3.3.3 Principle of the Affymetrix Genome-Wide Human SNP Array 5.0 
The Affymetrix Genome-Wide Human SNP Array 5.0 features 500,568 single 
nucleotide polymorphisms (SNPs) from the original two-chip Mapping 500K Array 
Set, as well as additional 420,000 non-polymorphic probes that can measure other 
genetic differences, such as copy number variations (CNV). SNPs on the array are 
present on 200 to 1,100 base pair (bp) Nsp I or Sty I digested fragments in the human 
genome, and are amplified using the fifth generation of the Whole-genome Sampling 
Assay (WGSA). Using the current 3.0.1 version of the Affymetrix Genotyping 
Console Software, a set of 440,794 SNPs on the array exhibit the performance 
capabilities. 
As it can be seen from the Figure 2, total genomic DNA (500 ng) is digested with Nsp 
I and Sty I restriction enzymes and ligated to adaptors that recognize the cohesive 4 bp 
overhangs. All fragments resulting from restriction enzyme digestion, regardless of 
size, are substrates for adaptor ligation. A genetic primer that recognizes the adaptor 
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sequence is used to amplify adaptor-ligated DNA fragments. PCR conditions have 
been optimized to preferentially amplify fragments in the 200 to 1,100 bp size range. 
PCR amplification products for each restriction enzyme digest are combined and 
purified using polystyrene beads. The amplified DNA is then fragmented, labeled and 
hybridized to a Genome-Wide Human SNP Array 5.0. (Genome-Wide Human Array 
SNP 5.0 Data Sheet) 
 
 
 
Figure 2. The fifth generation Whole-genome Sampling assay (Data Sheet Affymetrix 
Genome-Wide Human SNP Array 5.0) 
3.4 Hybridization 
Hybridization is a reaction where complementary DNA strands bind together. The 
sample DNA, or more usually PCR product derived from it, is labeled with a 
fluorophore so that the specific sites of hybridization on the microarray can be 
visualized and the intensity of the hybridization signal quantified. Success of 
hybridization requires suitable conditions and enough time. Conditions can be 
adjusted with hybridization buffers (e.g. pH) and hybridization temperature. 
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3.5 Principles of fluorescent microarray scanning 
Currently the technologies used to image microarrays are detection systems for 
absorbance, fluorescence or luminescense quantification. Fluorescently labeled 
microarrays can be easily “read” with commercially available scanners. Laser-based 
systems use motion control elements to scan the laser beam across the sample and 
photomultiplier tudes (PMTs) to collect emitted light one pixel at a time. White-light-
based systems use mercury or xenon arc lamps to excite an entire field of view and a 
chargedcoulped device (CCD) to capture emitted light from the entire field of view.  
In fluorescence imaging system excitation light is provided by either a halogen arc 
lamp or a laser. The light is delivered to the sample through a series of lenses and 
filters. The fluorophore on the sample emits light, which then travels through 
additional lenses and filters to the detector (a CCD or PMT). The analog signal from 
the detector is converted into a digital signal, which is then used to display an image 
of the sample on the computer screen. 
3.5.1 Background substraction  
The fluorescence intensity that is measured in a feature usually includes a certain 
amount of a stray light from various sources which can be auto-fluorescence of the 
slide or a non-specific binding of a labeled sample to the microarray substrate. This 
stray fluorescence, known as background, needs to be accounted for in order to 
calculate a true measure of the fluorescence in a feature. There are many methods for 
removing background from microarray images but each of them has advantages and 
disadvantages.  
Local background substraction methods, which are most commonly used, calculate a 
unique background value for each feature from a region near the feature. The 
advantage of local methods is that they substract only the nearby background from 
each feature. However, if there are artifacts or binding variations near or within a 
feature, local methods may produce extremely high or low background values. 
Global background substraction methods calculate a single value for each wavelength. 
The advantage of these methods is that they provide single background estimation for 
the whole slide but as a disadvantage, if the background varies significantly across a 
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slide, one single estimate may not accurately represent the background contribution to 
all features.  
Negative control background subtraction methods calculate a background value from 
the intensity of specified negative-control features. These methods have several 
advantages over local and global methods. For example, non-specific binding may 
differ where features have been printed on a slide, compared to the space between 
features. In such cases one can estimate non-specific fluorescent background from 
negative-control features rather than from local regions between features. However, 
unlike all the other background subtraction methods, the disadvantage to using these 
methods is that they must be included in the microarray slide design from the 
beginning. They should also be distributed widely on the array and can therefore take 
up a lot of space.  
There are also other methods, such as morphological methods, in which a copy of 
each single-wavelength image is created and then each image is filtered to construct a 
background image for each wavelength. The two standard morphological methods are 
Opening (where a local minimum filter is applied to the whole image) and Closing 
followed by Opening (where small dark regions are filled in on the background image, 
and then a local minimum filter is applied to the whole image).  
The problem with background subtraction is that it can add noise and dye bias to a 
microarray. Another problem with some background subtraction methods is that the 
result can depend upon the segmentation method used to separate foreground signal 
from background. If the segmentation method is wrong for the image, foreground 
intensity can be counted as background. For all these reasons there are these days a 
model-based method that estimates the true intensity of a spot by modeling the 
contribution of the background, or background adjustments are not used at all (DNA 
Microarrays, Nuber 2005). 
3.6 Data analysis 
Data analyzing is the stage of the microarray technology where results are to be 
analyzed and the meaning of the results is worked out. A DNA microarray can contain 
hundreds of thousands of spots with a huge amount of data from just one sample. All 
of this data needs to be somehow handled and for this purpose special computer 
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programs have been developed. There are quite many different kind of programs 
available and even programs that do all that is needed to analyze a DNA chip. Most of 
the smaller programs are available for academic use only and usually larger programs 
are commercial (Kulta A. 2002).  
3.6.1 Normalization 
Normalization is the process of removing errors (bias) from a measurement. The data 
from each spot on the array is usually normalized, which means that intensity ratio 
value is set to some specific range and so different microarray results become 
comparable to each other. Data on a microarray could be biased for several reasons 
such as differences in dye properties, probe labeling or for example in hybridization 
efficiencies. Normalization can be made using either data from user-selected probe 
sets or all probe sets.    
3.6.2 Clustering 
Clustering is a commonly used term in microarray technology. Clustering means 
grouping of the similar genes into groups with a mathematical algorithm. Clustering is 
the next thing to do after the spots have been normalized. 
There are different types of clustering. Commonly used algorithms are Hierarchical 
clustering, K-means clustering and SOM (self-organizing map based clustering). 
Hierarchical clustering algorithm clusters data of N items into a single cluster of size 
N by pairing two most similar items (or clusters) into a single cluster. This is repeated 
so many times that there is only one cluster left. K-means clustering algorithm clusters 
data into a predetermined number (K) of clusters. Self-organized map is an 
unsupervised neural network algorithm. Self-organized map clusters data into cells 
and the distance between cells refers to the similarity of the data in cells: the higher 
the distance is between two cells, the more different is the data in those cells. (Pavan 
K. 2008) 
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3.6.3 Quality control 
Quality control are performed using various measures and visualization techniques for 
estimating the quality and sample relationships in the data. If some samples clearly 
deviate from others, these samples may be considered to be called outliers and 
excluded from further analysis. 
Quality control performed before genotyping is called Single Chip Quality Control. 
The QC call rate for individual array is used to determine whether a sample should be 
repeated or used for downstream analysis. In this trial run 3022 SNPs tiled as PM 
(perfect mach) and MM (mismatch) probes (1511 for Nsp and 1511 for Sty) are tested 
(Figure 3). These 3022 SNPs are specifically chosen for evaluating data quality and 
QC call rate is generated by using the Dynamic Model algorithm (DM). Cutoff for 
passing samples is set to 86%. The arrays that pass the QC call rate will be analyzed 
using the BRLMM-P algorithm and the majority of the Genome_Wide SNP 5.0 
samples that meet this 86% specification will have a BRLMM-P genotyping call rate 
of at least 96% and accuracy. The QC analysis provides an estimate of the overall 
quality for a sample. This analysis provides a quick preview of data quality before 
performing a full clustering analysis. (Affymetrix Genome-Wide Human SNP Array 
5.0 Data Sheet)  
 
Figure 3. Scanned image of Genome-Wide Human SNP Array 5.0. Array is divided 
into four quadrants and the genotyping probes are tiled within each quadrant. 
(Affymetrix® Genome-Wide Human SNP Nsp/Sty Assay 5.0 Manual) 
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3.6.4 Genotype calling 
Highly accurate and reliable genotype calling is an essential component of high 
throughput SNP genotyping technology. In this genotyping calling determination was 
used BRLLM-P algorithm. BRLLM-P performs a multiple chip analysis, enabling the 
simultaneous estimation of probe effects and allele signals for each SNP. This step is 
retained even in arrays employing multiple copies of the same probe, even though the 
probe specific effects are only minimally different between copies. The distribution of 
summary values across arrays is then used to evaluate the likely genotypes. 
BRLMM-P algorithm call genotypes by a template-matching procedure comparing the 
transformed allele signal values observed in an experiment to the typical values, 
prototypes that are expected for each genotype. The genotype that is estimated to have 
the highest probability of having produced the data point is reported as the call. The 
approximate confidence that is reported for that call is the estimated probability that 
the data point belongs to one of the other clusters. These allow ranking the genotype 
assignments by quality, and therefore make the decision not to call in cases of 
ambiguity.  
Every SNP is expected to have three genotypes, “AA”, “AB”, and “BB”. For each 
genotype for a given SNP is expected to have a prototype with some scatter of values 
around the prototype. Prototype is a typical observed value for that specific genotype 
or cluster center. The scatter is approximated by a normal distribution. The relative 
probability of belonging to a cluster is calculated as a function of the distance from the 
cluster center and the variation within the cluster. In the end, the standard settings of 
BRLMM-P calculate a common variance for all clusters (BRLMM-P: Genotype 
Calling Method for the SNP 5.0 Array, 2007). 
3.6.5 Hardy-Weinberg equilibrium   
Hardy-Weinberg equilibrium (HW) is a basic principle of population genetics. 
According to HW the genotype frequencies at particular gene locus will become fixed 
at certain equilibrium value resulting from random mating under conditions were 
sexually reproducing organism is diploid and the species has distinct generations. It is 
however important to understand that outside the lab, one or more of disturbing 
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influences like mutations, non-random mating, selection or limited population size are 
always in effect. Genetic equilibrium is an ideal state that provides a baseline to 
measure genetic change against. The equilibrium values are depicted by a 
mathematical function (p
2
+2pq+q
2
=1) of the allele frequencies (p and q) at a particular 
locus. (Hardy 2003). 
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4 METHODS OF LABORATORY WORK 
4.1 Case and control selection  
From the table below (Table 4) details of the sample group specification can be seen. 
  
Tabel 4. Group description 
Group of cases Inclusion criteria 
A: DIPP Ab positive cohort HLA Genotype DRB1*0401-DQB1*0302 
T1D 
IAA as the first positive biochemical Ab:  
IAA positive 2x consecutively 
B: DIPP Ab positive cohort- 
GAD antibody group 
HLA Genotype DR3-DQA1*05-DQB1*0201 
positive (DR3/DR401; DR3/DR404; DR3 boys) 
T1D and at least three Abs positive two times 
consecutively (GADA + two others) 
C: DIPP Ab positive cohort  Like group A, but no T1D and at least three Abs 
positive two times consecutively (IAA + two 
others) 
D: DIPP Ab positive cohort- 
GAD antibody group 
Like group B, but no T1D but at least three Abs 
positive two times consecutively (GADA + two 
others) 
Genetic isolates T1D  
Kuusamo, Koillismaa 
Kainuu 
2 or more grandparents are from these regions 
 
Controls were matched by HLA, gender, geographic region and by following up time 
which should be longer than 10 years. The project covered 154 case samples and 92 
control samples. 
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4.2 Sample collection  
DNA was collected from the DIPP-project library. The DNA had originally been 
isolated from newborns’ navel blood samples and preserved in MediCity in -70 ºC.   
General requirements for the sample DNA were that the DNA had to be double-
stranded and free of PCR inhibitors. The DNA must not have been contaminated by 
other human genomic DNA sources, or by genomic DNA from other organisms. The 
DNA must not have been degraded. The success of this assay required the 
amplification of PCR fragments between 200 and 1100 bp in size throughout the 
genome. To reach this requirement, the genomic DNA needed to be of high quality 
and free of contaminants because it would otherwise affect on the enzymatic 
reactions.  
4.3 Sample preparation 
DNA was isolated by following the “DNA isolation protocol” by CellScreen 
Laboratory of Immunogenomics. 8ml of ice-cold redblood-lysis buffer (2x blood 
volume) was added in to 4 ml of blood (in a 15 ml falcon-tube) and centrifuged at 4ºC, 
2 500 rpm 10 min. Supernatant was poured out into a Heamasol bucket and 1 ml of 
MQW was added into the falcon-tube. The tube was centrifuged at 4ºC, 13 000 rpm, 1 
min and the wash step was repeated until the color of the pellet had turned 
homogeneously salmon. 370 µl of proteinase K-mix was added to the sample, shaken 
and incubated for 15 min at 55 ºC. After that 100 µl of 5M NaCl was added and 
centrifuged at 4ºC 13 000 rpm for 5 min. Then supernatant was transferred into a new 
2 ml eppendorf tube, 1 ml of ice-cold abs. Ethanol was added and the sample was 
mixed. In this step DNA precipitation was visible and after that DNA was transferred 
into a new 1.5 ml eppendorf tube containing 1 ml of ice-cold 70% Ethanol. In the end 
DNA is moved from the ethanol and dried at 37 ºC. 200 µl of TE was added to each 
sample DNA and incubated at 37 ºC over night.   
After DNA isolation samples were prepared by diluting each sample to 50 ng/µl using 
reduced EDTA TE buffer. 
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4.4 Sample Quality Control 
Sample quality assurance was performed in two ways. Samples were tested by allele 
specific PCR using HLA-B*62 gene as a control band and genomic DNA was run on 
a gel to assure that the DNA was intact. 
4.4.1 Allele specific PCR 
Samples were tested by allele specific PCR (Table 5) using the HLA-B*62 gene as a 
control band. The purpose of this method was to assure that the DNA was in a good 
condition and would be duplicated in the actual PCR. 
 
Tabel 5. Allele specific PCR program 
 For one sample / (µl) For 200 samples / (µl) 
H2O 12.52 2504 
10 x ABgene buffer 2.10 420 
10 mM dNTP-mix 0.42 84 
10 µM B62 243 F 0.63 126 
10 µM B62 250 R 0.63 126 
10 µM C63 F 0.32 64 
10 µM C64 R 0.32 64 
25 mM MgCl2 3.36 672 
5 U/µl ABgene Taq 
polymerase 
0.10 20 
 
PCR MasterMix was pipeted on a 96-well plate 20.4 µl/well. The A1 well contained 
1.5 µl B62+ control (20ng/µl), the A2 well 1.5 µl B62- control (20ng/µl) and the A3 
well 0.6 µl H2O. The samples were pipeted in the same order in which they were on 
the sample-plate. The sample wells contained 0.6 µl (50ng/µl) sample solution + 0.6 
µl H2O. PCR was performed by using the B62NEW66 PCR protocol (Table 6). 
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PCR protocol: Program name B62NEW66 
Duration 1h 30min 
Control method: Block 
 
Tabel 6. PCR program of B62NEW66 
1 96 ºC 1 min 
2 96 ºC 25 s 
3 66 ºC 50 s 
4 72 ºC 45 s 
5 Go to 2 30 times 
6 7 ºC for ever 
7 END  
 
After PCR the samples were run and analyzed on 2% agarose gel. 
4.4.2 Agarose gel electrophoresis for Genomic DNA 
The prepared 50 ng/µl sample-DNA was run and analyzed on 2% agarose gel. The 
DNA in the gel was detected by using Invitrogen’s SYBR Safe DNA gel stain, which 
glow brightly when bound to double stranded DNA and exposed to blue light. 
Samples were prepared by adding 5 µl of sample-DNA (250 ng) and 1 µl of a loading 
dye (6xBromofenolisine-sucrose). The gel was loaded totally of 249 6 µl samples and 
GeneRuler 1kb DNA ladder in the both sites of the gel. The gel was run at 160 V for 
an hour. Before viewing the gel it was divided into four pieces for fitting into a 
BioRad Imager. 
4.5 Restriction enzyme digestion 
The genomic DNA was digested by the Sty I restriction enzyme. After preparation of 
the Sty Digestion Master Mix, 14.75 µl of Master Mix was added to 5 µl of each DNA 
sample. The 48 samples included 46 genomic DNA samples and one positive and one 
negative control. Each plate was placed onto a thermal cycler and run by the GW5.0 
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Digest Program (Table 7). Digestion of genomic DNA by Nsp I restriction enzyme 
was performed simultaneously with Sty I digestion. It was performed by a different 
person to avoid contamination. After preparation of the Nsp Digestion Master Mix, 
14.75µl of it was added to one set of 48 samples (5µl of each sample). The plate was 
placed onto a thermal cycler and run by the GW5.0 Digest Program (Table 7). 
Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise amounts and workflow of this 
step can be found in the manual. 
 
Tabel 7. Digestion PCR program 
GW5.0 Digest Program 
Temperature Time 
37 ºC 120 minutes 
65 ºC 20 minutes 
4 ºC Hold 
 
4.6 Ligation 
The digested samples were ligated simultaneously using Sty and Nsp Adaptor. After 
preparing Sty Ligation Master Mix and Nsp Ligation Master Mix, they were both 
added to their own plates with samples. The samples were placed onto a thermal 
cycler and run by the GW5.0 Ligate Program (Table 8). After the program the ligated 
samples were diluted with 75 µl of AccuGENE water. 
 
Tabel 8. Ligate PCR program 
GW5.0 Ligate Program 
Temperature Time 
16 ºC 180 minutes 
70 ºC 20 minutes 
4 ºC Hold 
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Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise workflow of this step can be 
found in the manual.  
4.7 Sty and Nsp PCR 
Equal amounts of each Sty ligated sample were transferred into three fresh 96-well 
plates (Figure 4). Sty PCR Master Mix was added to each sample and each plate was 
placed on a thermal cycler and GW 5.0 PCR Program was run (Table 9). 
 
Figure 4. Transferring equal aliquots of diluted, ligated Sty samples to three reaction 
plates (Affymetrix® Genome-Wide Human SNP Nsp/Sty Assay 5.0 Manual) 
Likewise, equal amounts of each Nsp ligated sample was transferred, but in this case 
into four fresh 96-well plates. Nsp PCR Master Mix was added to each sample and 
each plate was placed on a thermal cycler and GW 5.0 PCR Program (Table 9) was 
run. 
 
Tabel 9. Sty and Nsp PCR program 
GW 5.0 PCR Program 
Temperature Time Cycles 
94 ºC 3 minutes 1 X 
94 ºC 30 sec  
30 X 60 ºC 30 sec 
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68 ºC 15 sec 
68 ºC  7 minutes 1 X 
4 ºC Hold  
 
After finishing the GW 5.0 PCR Program, PCR products were run on 2% TBE 
agarose gel at 160 V for 1 hour for verifying that the PCR product distribution is 
between ˜ 250 bp to 1100 bp.  
Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise workflow of this step can be 
found in the manual. 
4.8 PCR-product pooling and purification 
Sty and Nsp PCR reactions were pooled to a single deep well pooling plate (Figure 5), 
for a total of 700 µl/well. The magnetic beads were added to each pool and incubated. 
During incubation, the DNA binds to the magnetic beads. Each pool was transferred 
to a filter plate and dried down on a vacuum manifold. PCR products were washed 
with EtOH and dried down again. PCR products were eluted using Buffer EB and 
vacuumed end spin transferred to a new 96-well plate.  
Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise workflow of this step can be 
found in the manual. 
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Figure 5. Pooling Sty and Nsp PCR product on a deep well pooling plate 
(Affymetrix® Genome-Wide Human SNP Nsp/Sty Assay 5.0 Manual) 
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4.9 Qantitation 
The concentration of PCR products after purification with magnetic beads was 
measured using a spectrophotometer (NanoDrop
®
). One dilution of each PCR product 
was prepared in optical plates as a 100-fold dilution. The OD of each PCR product 
was measured at 260 nm.  
4.10 Fragmentation 
PCR products were fragmented using Fragmentation Reagent. First Fragmentation 
Reagent was diluted by adding the Fragmentation Buffer and AccuGENE water. After 
that the diluted reagent was quickly added to each reaction, placed the plate onto a 
thermal cycler and the GW5.0 Fragment Program (Table 10) was run. When the 
program was completed the results of this stage was checked by running 1.5 µl of 
each reaction on a 4% agarose gel. 
 
Tabel 10. Fragmentation PCR program 
GW5.0 Fragment Program 
Temperature Time 
37 ºC 35 minutes 
95 ºC 15 minutes 
4 ºC Hold 
 
Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise workflow of this step can be 
found in the manual. 
4.11 DNA labeling 
The fragmented samples were labeled using the DNA Labeling Reagent. After 
preparing the Labeling Master Mix the 19.5 µl of Master Mix was added to each 
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sample. The samples were placed onto a thermal cycler and the GW5.0 Label Program 
(Table 11.) was run.  
 
Tabel 11. Labeling PCR program 
GW5.0 Label Program 
Temperature Time 
37 ºC 4 hours 
95 ºC 15 minutes 
4 ºC Hold 
 
Laboratory working was performed by following the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. The precise workflow of this step can be 
found in the manual. 
4.12 Target hybridization 
Hybridization is the most critical step in microarray experiment. In this stage, each 
reaction was loaded onto a Genome-Wide Human SNP Array 5.0.  
Before loading arrays they were prepared by unwrapping and marking. Arrays were 
allowed to warm to room temperature by leaving them on the table for 15 minutes. A 
200 µl pipette tip was inserted into the upper right septum of the each array.  
The Hybridization Master Mix was prepared according to Table 12. 
 
Tabel 12. Hybridization Master Mix 
Reagent 1 Array 48 Arrays  
(15 % extra) 
MES (12X;1.25 M) 12 µl 660 µl 
Denhardt’s Solution (50X) 13 µl 715 µl 
EDTA (0.5 M) 3 µl 165 µl 
HSDNA (10 mg/ml) 3 µl 165 µl 
OCR, 0100 2 µl 110 µl 
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Human Cot-1 DNA®      
(1 mg/ml) 
3 µl 165 µl 
Tween-20 (3%) 1 µl 55 µl 
DMSO (100%) 13 µl 715 µl 
TMACL (5 M) 140 µl 7.7 ml 
Total 190 µl 10.45 ml 
 
After preparation of Hybridization Master Mix, 190 µl of Master Mix was added to 
each sample on the Label Plate. Now the total volume in each well was 263 µl. After 
vortexing and spinning the plate to assure that the sample was mixed properly, the 
plate was placed onto the thermal cycler and the GW5.0 Hyb Program (Table 13). 
 
Tabel 13. Hybridization PCR program 
GW5.0 Hyb Program 
Temperature Time 
95 ºC 10 minutes 
49 ºC Hold 
 
When the plate reached 49 ºC, 200 µl of denatured sample was removed from each 
well and immediately injected – one sample per array. The loading of the arrays was 
processed in 4 array sets so that 4 arrays were loaded at a time and then immediately 
placed into the hybridization oven. The hybridization oven was preheated to 50 ºC. 
The goal was not to allow loaded arrays to stand at room temperature for more than 
1.5 minutes. Samples were left to hybridize for 16 to 18 hours. The target 
hybridization was performed in two days so that 32 arrays were hybridized on one day 
and on the other 14 arrays. Positive and negative controls were not loaded on the 
arrays. 
The precise workflow of this step can be found in the Affymetrix
® 
Genome-Wide 
Human SNP Nsp/Sty Assay 5.0 Manual. 
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4.13 Washing and staining arrays 
Washing and staining steps were carried out by using GeneChip
®
 Fluidics Station 450 
(Figure 6) and it was operated using GeneChip
®
 Operating Software 1.4. The 
Affymetrix staining protocol for mapping arrays was a three stage process which 
consisted of 1) Streptavidin Phycoerythin (SAPE) stain, 2) an antibody amplification 
step, and 3) a final stain with Streptavidin Phycoerythin (SAPE). All three solutions 
were placed on the Fluidics Stations into the sample holders 1, 2 and 3 in vials. Before 
starting the program, the fluidics station was primed to ensure that the lines were filled 
with the appropriate buffers and the fluidics station was ready to run fluidics station 
protocols.  
 
 
Figure 6. Fluidics Station 450 
 (http://www.affymetrix.com/products_services/instruments/specific/fs450.affx) 
When the hybridization was ready, the hybridization cocktail was removed from the 
array and transferred to the corresponding well of a 96-well plate. The array was then 
filled completely with 270 µl of Array Holding Buffer and placed into the designated 
module of the Fluidics Station. The Fluidics Station method protocol is shown in 
Table 14. 
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Tabel 14. Fluidics Station 450 Protocol – Antibody Amplification for Mapping targets 
(Affymetrix
® 
Genome-Wide Human SNP Nsp/Sty Assay 5.0 Manual) 
49 Format (Standard) GenomeWideSNP5v1_450 
Post Hyb Wash #1 6 cycles of 5 mixes/cycle with Wash Buffer A at 25 ºC 
Post Hyb Wash #2 24 cycles of 5 mixes/cycle with Wash Buffer B at 45 ºC 
Stain Array is stained for 10 minutes in SAPE solution at 25 ºC 
Post Stain Wash 6 cycles of 5 mixes/cycle with Wash Buffer A at 25 ºC 
2
nd
 Stain Array is stained for 10 minutes in Antibody Stain Solution 
at 25 ºC 
3
rd
 Stain Array is stained for 10 minutes in SAPE solution at 25 ºC 
Final Wash 10 cycles of 6 mixes/cycle with Wash Buffer A at 30 ºC. 
The final holding temperature is 25 ºC 
Filling Array Array is filled with Array Holding Buffer.  
 
Wash Buffer A = non-stringent wash buffer       
Wash Buffer B = stringent wash buffer 
 
After followed staining, the array was filled with Array Holding Buffer prior to 
scanning. Before loading array in scanner, arrays window was checked for large 
bubbles or air pockets. If bubbles or air pockets were present, the array was placed 
back in Fluidics Station and refilled with Array Holding Buffer. 
4.14 Scanning arrays 
Scanning was performed by using the GeneChip
®
 Scanner 3000 7G and it was also 
controlled by GCOS Software 1.4. The glass surface of the array was cleaned with the 
non-abrasive towel before scanning and both septa on the array were carefully covered 
with Tough Spots (Figure 7).  
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Figure 7. Applying Tough Spots to arrays (Affymetrix® Genome-Wide Human SNP 
Nsp/Sty Assay 5.0 Manual) 
After placing the arrays in the scanner and selecting the right experiment, the Start 
button was clicked and scanning was started. The scanning of one array lasted 
approximately 11 minutes. 
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5 DATA ANALYSIS 
5.1 Scanning the arrays 
Microarrays were scanned by using GeneChip
®
 Scanner 3000 7G which is controlled 
by GCOS Software 1.4. After scanning, the program produced among other file types 
an image file of each scanned array (.dat file) and after that the array data were ready 
for analysis. 
5.2 Genotyping 
The Affymetrix Genotyping Console (GTC) was used to determine genotyping calls 
for the analyzed samples. Samples were processed in four groups (Table 15). The 
GTC 3.0.1 version included a BRLMM-P algorithm, which was used to determine 
genotyping calls for SNP Array 5.0. With the help of the GTC it was possible to 
display metrics and annotation information in standard tabular form, to evaluate the 
data quality for each array.  
 
Tabel 15. Sample groups 
Samples were processed in four groups: 
Group 1 21 DR3 cases + 23 DR3 controls 
Group 2 59 DR4 cases + 62 DR4 controls 
Group 3 63 Genetic Isolate cases + all 85 controls (DR3 and DR4) 
Group 4 All samples: 153 cases + 92 controls 
 
For each group its own Workspace was created as a working platform. The data files 
CEL, GQC and ARR were added in to each Workspace from selected arrays. Before 
running the genotyping, Quality Control Call Rate was determined and the threshold 
for passing samples was set to be >86%. All arrays that passed this value continued to 
the genotyping part. Genotyping analysis configurations were set to use the BRLMM-
P algorithm, the score threshold was set as 0.05 and Block size as 0. After genotyping, 
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results were reviewed by running per-SNP QC filtering were SNPs that had less per-
SNP call rate than 95% threshold were removed.  
5.3 Single Point Association Test 
Single point association tests were performed by using Bioconductor which is based 
on the statistical R programming language. With the help of this software it was 
possible to determine statistically the most significant SNPs of all 500,568. At the end 
the results were additionally examined with the Hardy-Weinberg p-value.  
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6 RESULTS 
6.1 Results of the laboratory experiments 
6.1.1 Sample Quality Control 
Results of sample quality control were determined by running 2% agarose gel 
electrophoresis. There were totally 6 quality control plates. 
6.1.1.1 Allele specific PCR 
In the gel picture (Figure 8) it can be seen that if there is an upper bright band (~1000 
bp), the sample has been amplified. The second band (~150 bp) tells that the sample is 
positive for B*62 (which is irrelevant in this determination). If there is no band, the 
sample has been amplified and so it has to be disqualified. All samples that were 
amplified were forwarded to agarose gel electrophoresis for Genomic DNA.  
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Figure 8. Agarose gel results of allele specific PCR, plates 5 and 6 
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6.1.1.2 Agarose gel electrophoresis for Genomic DNA 
As an assumption, high quality genomic DNA should be run as a major band at 
approximately 10-20 kb on the gel. In the gel picture it can be seen that if there is the 
upper bright band (~10 kb), the sample has multiplied and its quality is high.  
In the picture (Figure 9), in the second row of samples, sample E5 883 has not 
amplified and is seen as a smear. This means that the sample DNA is degraded which 
is why the sample is disqualified. All samples that had major band at 10kb were 
continued to restriction enzyme digestion. 
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Figure 9. Agarose gel results of genomic DNA, plates 5 and 6 
6.1.2 Sty and Nsp PCR 
To verify the Sty and Nsp PCR reactions, samples were run on 2% TBE agarose gel 
(Figure 10). By reading the gel from right to left, the negative control is seen at the 
fourth well in every row, at the second well the positive control and the last well of 
every row is GeneRuler 100 bp DNA Ladder. The highest band of the ladder is 1000 
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bp and the lowest 100. As it can be seen from the picture, the average product 
distribution is approximately between ~200 to 1100bp as it was required. The samples 
that had wide smear were multiplied and continued to pooling and purification.  
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Figure 10. plates 1,2 and 3 PCR products on 2% TBE agarose gel at 160V for 1 hour. 
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6.1.3 Fragmentation 
To ensure that fragmentation was successful, results were checked by running each 
reaction on ready-made 4 % TBE gel (Figure 11). First and last samples at the gel 
were GeneRuler 100 bp DNA ladder. By reading the gel from the right to left, the 
second well was positive control and third well negative. Those samples that 
multiplied continued to labeling stage. 
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Figure 11. Fragmentation PCR product run on 4 % TBE agarose gel at 120V for 1 
hour. Average fragment size is < 200 bp. 
6.2 Microarray scanning 
GeneChip Scanner 3000 7G automatically scanned microarrays and produced scanned 
image file (.dat file) for analysis. Totally of all 300 scanned microarrays 246 passed 
the quality controls and automatic generation of CEL. Files were made. Most of the 
failed arrays had low SNP call rates which might had been result of not optimal 
genomic DNA.   
There were also problem with one series of 48 arrays, in which after scanning 
occurred that no labeling had happened. The problem appeared in the wrong order of 
Fluidic Station solutions. Because of that arrays were rehybridized, washed, stained 
and scanned again. 
           37 
6.3 Data analysis 
Data produced by GeneChip Scanner 3000 7G and GCOS Software 1.4 was 
transferred to Affymetrix Genotyping Console 3.0.1 for further processing.  
6.3.1 Reviewing CEL data Quality 
All of 246 arrays passed the set quality control threshold of > 86%. The arrays were 
processed in four groups (see table 15) with their own Workspaces. Each Intensity 
Quality Control Data was demonstrated as a matrix and graph. Intensity Quality 
Control graphs of groups 1 and 3 can be seen below in Graphs 1 and 2. 
 
 
Graph 1. Intensity QC data of Group 3 (Genetic Isolates + all controls) 
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Graph 2. Intensity QC data of Group 1 (DR3 cases + DR3 controls) 
 
6.3.2 Genotyping 
When the genotyping analysis was completed, the CHP summary statistics (genotype 
calls) was displayed as a table and the line graph (Graph 3) could be drawn from this 
data. Standard table operations included selecting which columns to display, sort or 
search and export to clipboard or file.  
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Graph 3. CHP summary data of genotyping results of Group 4 (All samples) 
 
6.3.3 Reviewing CEL data quality 
After genotyping of all four groups, results were reviewed by running per-SNP QC 
filtering were SNPs that had less per-SNP call rate than 95% threshold were removed 
(Table 16). Per-SNP clusters could visualize for every SNP (Graphs 4-6).   
 
Tabel 16. SNPs passed 95% call rate from total 500,568 SNPs 
Group 1 417 203 
Group 2 414 946 
Group 3 417 472 
Group 4 415 176 
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Graph 4. SNP_A-1780654 cluster graph from Group 1 (DR3 cases + DR3 controls). 
SNP_A1780654 is homogeneous to signal A 
 
 
Graph 5. SNP_A-1780520 cluster graph from Group 1 (DR3 cases + DR3 controls). 
SNP_A-1780520 is homogeneous to signal B 
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Graph 6. SNP_A-1781076 cluster graph from Group 1 (DR3 cases + DR3 controls) 
 
CHP file data and SNP summary data were exported to a text file for association 
analyses.  
6.3.4 Association analyses 
6.3.4.1 Single point association tests 
Results of Single Point Association tests could be seen in Table 17. 
 
Tabel 17. Results of single point association tests 
Group Significant SNPs  
(p-value threshold 
5.0E-3) 
Significant SNPs  
(p-value threshold 
5.0E-4) 
Significant SNPs  
(p-value threshold 
5.0E-5) 
Group 1 2171 189 19 
Group 2 3886 340 25 
Group 3 4391 445 39 
Group 4 4369 494 66 
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Tabel 18. Final results of statistically significant SNPs from all arrays  
p-value limit Number of significant SNPs 
0.05 40 257 
0.01 8 757 
0.005 4 369 
0.001 944 
5.0E-4 494 
1.0E-4 107 
5.0E-5 66 
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7 DISCUSSION 
7.1 Laboratory work 
Working with blood samples that are several years old is always a challenge and sets 
sometimes limitations in the starting material. In this case finding good samples in the 
database and isolating the DNA was a somewhat challenging because of this problem. 
However, the required amount of samples was successfully collected and the DNA 
fulfilled the requirements. The quality of the DNA was tested by two different 
methods to ensure that the DNA was free of inhibitors and not highly degraded.  
 
The stages involving enzymatic reactions were the most critical part of the assay. 
Successful performing of the various molecular biology steps in this protocol required 
accuracy and attention to details because many of the stages involved specific 
enzymatic reactions. For example in Sty and Nsp digestion and ligation two different 
persons performed these steps to avoid any kind of contamination. 
 
In the stage of purifying pooled PCR products by magnetic beds, problem appeared 
with some samples. During the filtering of the samples, some samples dried more 
quickly than others though the concentration of samples should have been the same. 
The problem might have been in the magnetic beads because they expired before all 
the series were accomplished. Another defect may have been in the vacuum 
equipment, the filtering plate did not always fit perfectly to the vacuum manifold 
causing deficiency in vacuum pressure. However, a more likely reason might still 
have been the deviation between the sample DNA concentrations.  
 
Other problems that were encountered during the protocol were the complication of 
staining during the washing step. Two SAPE staining solutions and an antibody stain 
solution got mixed up and were placed in the wrong order in the Fluidics Station. For 
that reason the staining of the arrays failed and during the scanning of the arrays it 
looked like no hybridization had taken place. When the problem occurred, the arrays 
were once again rehybridized, washed and scanned.  
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In the few unsuccessful array image scannings an error occurred on the image (Figure 
12). It seemed like there was a bubble or an air pocket in the array window although it 
didn’t look like it.  The solution was found in the amount of the loaded Array Holding 
Buffer and the pipeting amount was increased with 10 µl. 
 
 
Figure 12. Array image problem 
 
7.2 Data analysis 
Affymetrix Genotyping Console (GTC) and Bioconductor were easy and comfortable 
to use and array analysis did not present any bigger difficulties. GTC program 
demanded however efficient computer to process and produce such big amounts of 
data but after acquiring more memory the work was much readable.  
 
In this study, deviating from many other similar WGA studies, sample data was very 
strictly defined, which may bring us to more specific results concerning T1D. Results 
can be assumed reliable because they have been statistically examinated with the help 
of Hardy-Weinberg p-value and critically analyzed.  
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By results of this study we now know statistically significant SNPs and by that genes 
where they appear. In the future, with the help of these results, we can study role of 
those genes in T1D and possible find new essential genes which impact on this 
disease.
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APPENDICES 
 
Appendix 1. Group 1 SNP list with gene description  
Appendix 2. Group 2 SNP list with gene description 
Appendix 3. Group 3 SNP list with gene description 
Appendix 4. Group 4 SNP list with gene description 
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APPENDIX 1. 
 
SNP ID p-value Gene description 
1 4.24E-5 downstream//U2 spliceosomal RNA// Eukaryotic type 
signal recognition particle RNA 
2 2.40E-5 intron//CUB and Sushi multiple domains 2 
3 1.66E-5 upstream//Mal, T-cell differentiation protein 2// Collectin 
sub-family member 10 (C-type lectin) 
4 4.24E-5 intron//Pecanex-like 2 (Drosophila) 
5 4.05E-5 intron// Methionine sulfoxide reductase A 
6 4.24E-5 upstream// Ras association (RalGDS/AF-6) domain 
family (N-terminal) member 8 
7 1.66E-5 upstream// Adenylate cyclase 2 (brain)// LOC442132 // 
442132 // Similar to hypothetical protein FLJ36144 
8 1.97E-5 upstream// 7SK RNA 
9 2.49E-5 intron// ADAM metallopeptidase domain 23 
10 4.24E-5 downstream// Septin 8// Ankyrin repeat domain 43// 
Cyclin I family, member 2///upstream// Ankyrin repeat 
domain 43 
11 3.13E-5 upstream// Noggin//downstream// Ankyrin-repeat and 
fibronectin type III domain containing 1 
12 5.97E-5 downstream// Eukaryotic type signal recognition particle 
RNA// U2 spliceosomal RNA 
13 2.40E-5 upstream// CDC42 binding protein kinase alpha (DMPK-
like)// Serine/threonine-protein kinase MRCK alpha 
14 1.49E-5 downstream// Eukaryotic type signal recognition particle 
RNA// Branched chain aminotransferase 1, cytosolic 
15 1.97E-5 intron// Solute carrier family 39 (metal ion transporter), 
member 11 
16 2.40E-5 intron// Kazrin// kazrin isoform B 
17 2.40E-5 intron// Vacuolar protein sorting 53 homolog (S. 
cerevisiae) 
2 
 
18 4.24E-5 upstream// Y RNA///downstream// POU domain, class 4, 
transcription factor 1 (Brain-specific homeobox/POU 
domain protein 3A) 
19 3.83E-5 downstream// B-cell translocation gene 4 
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APPENDIX 2. 
 
SNP ID p-value Gene description 
111 
4,38E-05 
downstream// U7 small nuclear RNA//upstream// 
Phosphoinositide-3-kinase, class 3 
112 
4,42E-05 
downstream// Neurotrophic tyrosine kinase, receptor, type 
3// Transmembrane protein 83 
113 
4,01E-05 
downstream// U7 small nuclear RNA// CDNA FLJ45625 
fis, clone BRTHA3028505 
114 
4,44E-05 
upstream// 7SK RNA// U4 spliceosomal RNA 
115 
8,68E-06 
downstream// Zinc finger protein 273 
116 
4,82E-06 
intron// Cadherin 13, H-cadherin (heart) 
117 
3,61E-05 
intron// Fibroblast growth factor 14 (FGF-14) (Fibroblast 
growth factor homologous factor 4) (FHF-4) 
118 
1,58E-05 
Receptor accessory protein 1 
119 
2,76E-05 
intron// FERM domain-containing protein 5 
1110 
2,48E-05 
downstream// Periostin, osteoblast specific factor// 
1111 
2,66E-05 
intron// Tensin 1 
1112 
8,26E-06 
downstream// IMP2 inner mitochondrial membrane 
protease-like//upstream// Leucine rich repeat neuronal 3// 
IMP2 inner mitochondrial membrane peptidase-like (S. 
cerevisiae)// Hypothetical LOC154907 
1113 
3,66E-05 
upstream//- - - // 
1114 
1,27E-05 
intron// Cytoplasmic tyrosine-protein kinase BMX (EC 
2.7.10.2) (Bone marrow tyrosine kinase gene in 
chromosome X protein) 
1115 
3,87E-05 
downstream// U1 spliceosomal RNA// 5S ribosomal RNA 
1116 
3,66E-05 
Cannabinoid receptor 1//downstream// U17/E1 small 
nucleolar RNA// mRNA capping enzyme (HCE) 
(HCAP1) 
1117 
3,82E-05 
upstream//- - -// 
1118 
4,44E-05 
intron// Sorbin and SH3 domain-containing protein 1 
4 
 
(Ponsin) (c-Cbl-associated protein) (CAP) (SH3 domain 
protein 5) (SH3P12) 
1119 
4,62E-05 
downstream// Prostaglandin E receptor 3 (subtype EP3) 
1120 
1,41E-06 
intron// DiGeorge syndrome critical region gene 2// 
Integral membrane protein DGCR2/IDD precursor 
1121 
8,98E-06 
downstream// Chromosome 3 open reading frame 55 
1122 
3,69E-05 
upstream//- - -// 
1123 
7,26E-06 
upstream// Metallophosphoesterase domain containing 2// 
Doublecortin domain containing 5 
1124 
1,16E-05 
downstream// Hydroxysteroid (17-beta) dehydrogenase 6 
homolog (mouse) 
1125 
3,66E-05 
upstream// Adenosine deaminase, RNA-specific, B2 
(RED2 homolog rat)// Double-stranded RNA-specific 
editase B2 
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APPENDIX 3. 
 
SNP ID p-value Gene description 
1201 
3,98E-05 
downstream//CCR4-NOT transcription complex, subunit 
6-like//Chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) 
1202 
1,15E-06 
intron//Sarcoglycan zeta 
1203 
1,79E-06 
intron//Chondroitin beta-1,4-N-
acetylgalactosaminyltransferase 1 
1204 
1,88E-05 
upstream//Steroid sulfatase (microsomal), isozyme 
S//Haloacid dehalogenase-like hydrolase domain 
containing 1A 
1205 
1,02E-05 
downstream//- - - // 
1206 
1,05E-06 
upstream//D4, zinc and double PHD fingers, family 
3//WD repeat domain 21A 
1207 
2,56E-06 
downstream//2-oxoisovalerate dehydrogenase subunit 
beta, mitochondrial precursor (EC 1.2.4.4) (Branched-
chain alpha-keto acid dehydrogenase) 
1208 
2,56E-06 
intron//mitogen-activated protein kinase kinase kinase 15 
1209 
1,88E-05 
intron// RAB33A, member RAS oncogene family 
1210 
2,76E-05 
downstream//Diacylglycerol O-acyltransferase 2-like 
protein 6 
1211 
4,34E-06 
intron//Nuclear transcription factor, X-box binding-like 1 
1212 
3,99E-05 
intron//Ankyrin repeat and IBR domain containing 1 
1213 
5,23E-06 
downstream//Mdm1 nuclear protein homolog (mouse) 
1214 
1,07E-05 
intron//Slit homolog 3 (Drosophila)// Slit homolog 3 
protein precursor (Slit-3) (Multiple epidermal growth 
factor-like domains 5) 
1215 
2,70E-05 
upstream//RAB1A, member RAS oncogene family//U19 
small nucleolar RNA//downstream//Centrosomal protein 
of 68 kDa (Cep68 protein) 
1216 
8,08E-06 
intron//DDHD domain containing 1 
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1217 
4,15E-05 
downstream//Hyaluronan synthase 2//Syntrophin, beta 1 
(dystrophin-associated protein A1, 59kDa, basic 
component 1) 
1218 
4,20E-05 
downstream//Interleukin 17F//Interleukin-17F precursor 
(IL-17F) (Interleukin-24) (IL-24) (Cytokine ML-1) 
1219 
2,15E-05 
downstream//- - -// 
1220 
3,24E-05 
upstream//- - - // 
1221 
1,99E-05 
intron//C1orf112 protein//SCY1-like 3 (S. cerevisiae)// 
Chromosome 1 open reading frame 112 
1222 
3,52E-05 
SASH1//AM and SH3 domain containing 
1//upstream//Uronyl-2-sulfotransferase 
1223 
1,38E-05 
intron//Collagen, type XXI, alpha 1 
1224 
3,74E-05 
intron//Interleukin 18 (interferon-gamma-inducing factor) 
1225 
1,79E-05 
intron//Hypothetical protein FLJ21511 
1226 
2,33E-05 
downstream//U23 small nucleolar RNA//Transcribed 
locus//upstream//LIM domain-binding protein 2 
(Carboxyl-terminal LIM domain-binding protein 1) 
1227 
3,33E-06 
intron//Platelet-activating factor acetylhydrolase 2 
cytoplasmic, 40kDa//PAFAH2// 
1228 
1,05E-06 
intron//Cadherin 13, H-cadherin (heart) 
1229 
1,21E-05 
intron//SEC16 homolog A (S. cerevisiae) 
1230 
4,94E-06 
upstream//Cell adhesion molecule 2//immunoglobulin 
superfamily, member 4D 
1231 
3,18E-05 
downstream//Ubiquitin specific peptidase 31//Heparan 
sulfate (glucosamine) 3-O-sulfotransferase 2 
1232 
1,05E-06 
downstream//Family with sequence similarity 148, 
member B 
1233 
3,33E-06 
intron//F-box and leucine-rich repeat protein 7 
1234 
2,56E-06 
downstream//Chromosome 21 open reading frame 91//B 
lymphocyte activation-related protein BC-2048 
1235 
2,15E-05 
intron//Dachshund homolog 2 (Drosophila) 
1236 
4,68E-06 
upstream//- - -// 
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1237 
8,08E-06 
upstream//Oligonucleotide/oligosaccharide-binding fold-
containing protein 1//STE20-like serine/threonine-protein 
kinase 
1238 
3,31E-06 
downstream//5S ribosomal RNA//V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
1239 
8,16E-06 
intron//Schwannomin interacting protein 1 
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APPENDIX 4. 
 
SNP ID p-value Gene description 
1301 
1,24E-05 
downstream//Ubiquitin ligase protein FANCL (EC 
6.3.2.-) (Fanconi anemia group L protein)// Vaccinia 
related kinase 2// 
1302 
8,76E-06 
intron//Target of myb1-like 2 (chicken) 
1303 
3,79E-05 
upstream//Solute carrier family 10 (sodium/bile acid 
cotransporter family), member 2//D-amino acid oxidase 
activator 
1304 
1,99E-05 
downstream//Activating transcription factor 1 
1305 
4,28E-05 
downstream//TWIST neighbor//Fer3-like (Drosophila) 
1306 
4,17E-07 
intron//Protein tyrosine phosphatase, receptor type, K 
1307 
3,56E-05 
upstream//D-amino acid oxidase activator//Solute carrier 
family 10 (sodium/bile acid cotransporter family), 
member 2 
1308 
4,25E-05 
downstream//PDCD6 protein (Fragment)// 
Lysophosphatidylcholine acyltransferase 1 
1309 
4,32E-05 
downstream//U6 spliceosomal RNA//zona pellucida-like 
domain containing 1 
1310 
3,17E-05 
intron//CREB regulated transcription coactivator 3 
1311 
4,64E-06 
downstream//Interleukin 6 (interferon, beta 2) 
1312 
4,28E-05 
upstream//Y RNA// Meis homeobox 2 
1313 
2,59E-05 
downstream//Chromosome 10 open reading frame 
136//Chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1)// Stromal cell-derived factor 1 
precursor (SDF-1) (CXCL12) (Pre-B cell growth-
stimulating factor) (PBSF) (hIRH) 
1314 
4,25E-05 
60S ribosomal protein L37 
1315 
1,29E-05 
upstream//- - -// 
1316 
6,56E-06 
upstream//Lymphocyte antigen 86//Coagulation factor 
XIII, A1 polypeptide 
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1317 
2,08E-05 
upstream// Nuclear receptor interacting protein 1 
1318 
3,44E-06 
upstream//Guanylate cyclase 1, soluble, alpha 
2//CWF19-like 2, cell cycle control (S. pombe) 
1319 
1,09E-05 
upstream//Y RNA 
1320 
3,94E-05 
intron//Neurexin 1 
1321 
4,91E-05 
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 8 
1322 
4,33E-06 
intron//RNA binding motif, single stranded interacting 
protein 
1323 
2,79E-07 
intron//Latrophilin 2 
1324 
4,76E-05 
upstream//Family with sequence similarity 86, member 
A 
1325 
2,17E-05 
intron//Nibrin// Homo sapiens nibrin (NBN), transcript 
variant 2, mRNA 
1326 
2,20E-05 
intron//Forkhead box P1 
1327 
4,33E-06 
downstream//Poly(A) binding protein interacting protein 
2B//M-phase phosphoprotein 10 (U3 small nucleolar 
ribonucleoprotein) 
1328 
2,38E-05 
intron//Heparan sulfate 6-O-sulfotransferase 3 
1329 
3,31E-05 
downstream// Zic family member 1 (odd-paired 
homolog, Drosophila) 
1330 
4,30E-05 
upstream//ADAM metallopeptidase with 
thrombospondin type 1 motif, 3 
1331 
4,17E-07 
intron// Chromosome 12 open reading frame 50 
1332 
7,38E-06 
upstream//TRNA splicing endonuclease 2 homolog (S. 
cerevisiae)// Peroxisome proliferator-activated receptor 
gamma 
1333 
9,23E-06 
upstream//- - -//U6 spliceosomal RNA 
1334 
4,01E-05 
intron//Transcription factor 7-like 1 (T-cell specific, 
HMG-box) 
1335 
4,17E-07 
downstream//CDNA FLJ46681 fis, clone 
TRACH3010382// Polypeptide N-
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acetylgalactosaminyltransferase 17//Heat shock protein 
90Af 
1336 
1,94E-05 
Family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A4 
1337 
1,49E-06 
downstream//Receptor accessory protein 3// Leucine 
rich repeat transmembrane neuronal 3//Catenin 
(cadherin-associated protein), alpha 3 
1338 
3,59E-05 
upstream//C-type lectin domain family 2, member A 
1339 
4,17E-07 
intron// Monoacylglycerol O-acyltransferase 1 
1340 
4,17E-07 
upstream//Par-3 partitioning defective 3 homolog B (C. 
elegans)// Amyotrophic lateral sclerosis 2 chromosome 
region candidate gene 19 protein (Partitioning-defective 
3-like protein)// Inducible T-cell co-stimulator 
1341 
3,57E-05 
upstream//VPS10 domain-containing receptor SorCS1 
precursor (hSorCS)// 5S ribosomal RNA 
1342 
1,08E-06 
upstream//Serpin B5 precursor (Maspin) (Protease 
inhibitor 5)// Vacuolar protein sorting 4 homolog B (S. 
cerevisiae) 
1343 
1,29E-05 
upstream//Syntaxin 3// Olfactory receptor, family 10, 
subfamily V, member 1//Fatty acid-binding protein, 
epidermal (E-FABP) (Psoriasis-associated fatty acid-
binding protein homolog) (PA-FABP) 
1344 
2,65E-05 
upstream//Solute carrier family 19 (folate transporter), 
member 1//Chromosome 21 open reading frame 
123//Collagen, type XVIII, alpha 1 
1345 
4,17E-07 
upstream//Chromosome 15 open reading frame 
57//RNA pseudouridylate synthase domain containing 2 
1346 
2,79E-05 
downstream//U6 spliceosomal RNA//SP100 nuclear 
antigen 
1347 
2,25E-05 
downstream//U6 spliceosomal RNA//Chromosome X 
open reading frame 27//Huntingtin interacting protein 
HYPM (Fragment) 
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1348 
4,01E-05 
intron//X-ray repair complementing defective repair in 
Chinese hamster cells 5 (double-strand-break rejoining) 
1349 
3,31E-05 
upstream//Spermatogenesis associated 13 
1350 
1,16E-05 
intron// Plexin C1 
1351 
3,31E-06 
intron//V-set domain containing T cell activation 
inhibitor 1 
1352 
4,01E-05 
Hermansky-Pudlak syndrome 1 protein 
1353 
1,83E-06 
upstream//OPALIN//Oligodendrocytic myelin paranodal 
and inner loop protein//Tolloid-like 2//Transmembrane 
protein 10 
1354 
7,91E-07 
intron//Neurexin 3 
1355 
4,87E-05 
upstream//Pellino homolog 1 (Drosophila) 
1356 
5,41E-06 
intron//Mediator complex subunit 7 
1357 
3,26E-05 
intron//Na+/K+ transporting ATPase interacting 2 
1358 
2,28E-05 
intron//CDNA FLJ31737 fis, clone 
NT2RI2007084//Chromosome 10 open reading frame 
72 
1359 
1,26E-05 
intron//Roundabout, axon guidance receptor, homolog 2 
(Drosophila) 
1360 
4,25E-05 
intron//Sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 3 
1361 
2,71E-05 
intron//Catenin (cadherin-associated protein), alpha 3 
1362 
1,47E-05 
intron//ATPase, Ca++ transporting, plasma membrane 2 
1363 
6,98E-06 
upstream//- - -//downstream//5S ribosomal RNA 
1364 
4,17E-07 
downstream//Family with sequence similarity 84, 
member A//Neuroblastoma-amplified protein 
1365 
9,36E-07 
downstream//Iroquois homeobox 5 
 
